The assessment of oestrogen receptor (ERα), progesterone receptor (PR) and HER2 is routinely performed in every breast cancer patient for prognosis and to select candidates for hormonal and anti-HER2 therapy (Fig. 2A). The gene discussed is ERBB2; the disease is breast cancer.